ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 247-258

  Decker, Michael W ^a   Bannon, Anthony W ^a   Curzon, Peter ^a   Gunther, Karen L ^a   Brioni, Jorge D ^a   Holladay, Mark W ^a   Lin, Nan Horng ^a   Li, Yihong ^a   Daanen, Jerome F ^a   Buccafusco, Jerry J ^b,c   Prendergast, Mark A ^b   Jackson, William J ^b,c   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; CHOLINERGIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; DOSE RESPONSE; LOCOMOTION; MAZE TEST; MONKEY; NONHUMAN; PRIORITY JOURNAL; SPATIAL DISCRIMINATION;

ANIMALS; AVOIDANCE LEARNING; CHOLINERGIC AGENTS; COGNITION; DISCRIMINATION LEARNING; FEMALE; ION CHANNELS; MACACA NEMESTRINA; MALE; MAZE LEARNING; NICOTINE; PYRIDINES; PYRROLIDINES; RATS; RECEPTORS, NICOTINIC;

EID: 14444276048     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. ARAUJO, D. M., LAPCHAK, P. A., MEANEY, M. J., COLLIER, B. AND QUIRION, R.: Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: Relationship to presynaptic cholinergic markers and binding sites. J. Neurosci. 10: 3069-3078, 1990.
2. ARENDASH, G. W., SENGSTOCK, G. J., SANBERG, P. R. AND KEM, W. R.: Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674: 252-259, 1995.
3. ARNERIC, S. P., HOLLADAY, M. W. AND SULLIVAN, J. P.: Cholinergic modulators as a novel therapeutic strategy for Alzheimer's disease. Exp. Opin. Invest. Drugs 5: 79-100, 1996a.
4. ARNERIC, S. P., BANNON, A. W., BRIGGS, C. A., BRIONI, J. D., BUCCAFUSCO, J. J., DECKER, M. W., DONNELLY-ROBERTS, D. L., GOPALAKRISHNAN, M., HOLLADAY, M. W., KYNCL, J., LIN, N. H., MARSH, K. C., QUI, Y., RADEK, R., SULLIVAN, J. P. AND WILLIAMS, M.: ABT-089: An orally active cholinergic channel modulator with cognition enhancing and neuroprotective activity. In Alzheimer Disease: From Molecular Biology to Therapy, ed. by R. Becker, E. Giacobini and P. Robert, pp. 287-292. Birkhauser Boston Inc., New York, 1996b.
5. BAMMER, G.: Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: A review and some new results. Neurosci. Biobehav. Rev. 6: 247-296, 1982.
6. BANNON, A. W., CURZON, P., GUNTHER, K. L. AND DECKER, M. W.: Effects of intraseptal injection of 192-IgG-saporin on spatial learning in mature and aged rats. Brain Res. 718: 25-36, 1996.
7. BARTUS, R. T. AND JOHNSON, H. R.: Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol. Biochem. Behav. 5: 39-46, 1976.
8. BEATTY, W. W., BUTTERS, N. AND JANOWSKY, D. S.: Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav. Neural Biol. 45: 169-211, 1986.
9. BRIONI, J. D. AND ARNERIC, S. P.: Nicotinic receptor agonists facilitate retention of avoidance training: Participation of dopaminergic mechanisms. Behav. Neural Biol. 59: 57-62, 1993.
10. BRIONI, J. D., KIM, D. J. B., O'NEILL, A., BRODIE, M. S., DECKER, M. W. AND ARNERIC', S. P.: ABT-089[2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: Discriminative stimulus properties and electrophysiological actions. Drug Dev. Res., 40:259-266, 1997.
11. BUCCAFUSCO, J., JACKSON, W., TERRY, A., MARSH, K., DECKER, M. AND ARNERIC, S.: Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology 120: 256-266, 1995.
12. BUCCAFUSCO, J. J. AND JACKSON, W. J.: Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging 12: 233-238, 1991.
13. CHRISTENSEN, H., MALTBY, N., JORM, A. F., CREASEY, H. AND BROE, G. A.: Cholinergic "blockade" as a model of the cognitive deficits in Alzheimer's disease. Brain 115: 1681-1699, 1992.
14. COYLE, J. T., PRICE, D. L. AND DELONG, M. R.: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219: 1184-1190, 1983.
15. DECKER, M., BRIONI, J., BANNON, A. AND ARNERIC, S.: Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 56: 545-570, 1995a.
16. DECKER M. W., BRIONI, J. D., J. P. SULLIVAN, BUCKLEY, M. J., RADEK, R. J., RASKIEWICKZ, J. L., KANG, C. H., KIM, D. J. B., GIARDINA, W. J., WILLIAMS, M. AND ARNERIC, S. P.: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): A novel cholinergic ligand with cognition enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 270: 319-328, 1994a.
17. DECKER, M. W., CURZON, P. AND BRIONI, J. D.: Influence of separate and combined septal and amygdala lesions on memory, acoustic startle, anxiety, and locomotor activity in rats. Neurobiol. Learning Memory 64: 156-168, 1995b.
18. DECKER, M. W., CURZON, P., BRIONI, J. D. AND ARNERIC, S. P.: Effects of ABT 418, a novel cholinergic channel ligand, on learning and memory in septallesioned rats. Eur. J. Pharmacol. 261: 217-222, 1994b.
19. DECKER, M. W. AND MAJCHRZAK, M. J.: Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats. Psychopharmacology 107: 530-534, 1992.
20. DECKER, M. W., MAJCHRZAK, M. J. AND ANDERSON, D. J.: Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 572: 281-285, 1992.
21. DECKER, M. W., MAJCHRZAK, M. J. AND ARNERIC', S. P.: Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45: 571-576, 1993.
22. DILTS, S. L. AND BERRY, C. A.: Effect of cholinergic drugs on passive avoidance in the mouse. J. Pharmacol. Exp. Ther. 158: 279-285, 1967.
23. DRACHMAN, D. A.: Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 27: 783-790, 1977.
24. ELROD, K., BUCCAFUSCO, J. J. AND JACKSON, W. J.: Nicotine enhances delayed matching-to-sample performance by primates. Life Sci. 43: 277-287, 1988.
25. FLOOD, J. F. AND CHERKIN, A.: Scopolamine effects on memory retention in mice: A model of dementia? Behav. Neural Biol. 45: 169-184, 1986.
26. FONNUM, F.: A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24: 407-109, 1975.
27. FREEMAN, S. E. AND DAWSON, R. M.: Tacrine: a pharmacological review. Prog. Neurobiol. 36: 257-277, 1991.
28. GALLAGHER, M., BURWELL, R. AND BURCHINAL, M.: Severity of spatial learning impairment in aging: Development of a learning index for performance in the Morris water maze. Behav. Neurosci. 107: 618-626, 1993.
29. HODGES, H., ALLEN, Y., SINDEN, J., MITCHELL, S. N., ARENDT, T., LANTOS, P. L. AND GRAY, J. A.: The effects of cholinergic drugs and cholinergic-rich foetal neural transplants on alcohol-induced deficits in radial maze performance in rats. Behav. Brain Res. 43: 7-28, 1991.
30. JACKSON, W. J., ELROD, K. AND BUCCAFUSCO, J. J.: Delayed matching-to-sample in monkeys as a model for learning and memory deficits: Role of brain nicotinic receptors. In Novel approaches to the treatment of Alzheimer's disease, ed. by E. M. Meyer, J. W. Simpkins and J. Yamamoto, pp. 39-52, Plenum Publishing Corporation, New York, 1989.
31. JONES, G. M. M., SAHAKIAN, B. J., LEVY, R., WARBURTON, D. M. AND GRAY, J. A.: Effects of acute subcutaneous nicotine on attention, information processing short-term memory in Alzheimer's disease. Psychopharmacology 108: 485-494, 1992.
32. KESNER, R. P., BOLLAND, B. L. AND DAKIS, M.: Memory for spatial locations, motor responses, and objects: triple dissociation among the hippocampus, caudate nucleus, and extrastriate visual cortex. Exp. Brain Res. 93: 462-470, 1993.
33. LEVIN, E. D.: Nicotinic systems and cognitive function. Psychopharmacology 108: 417-431, 1992.
34. LIN, N.-H., GUNN, D. E., RYTHER, K. B., GARVEY, D. S., DONNELLY-ROBERTS, D. L., DECKER, M. W., BRIONI, J. D., BUCKLEY, M. J., RODRIGUES, A. D., MARSH, K. G., ANDERSON. D. J., BUCCAFUSCO, J. J., PRENDERGAST, M. A., SULLIVAN, J. P., WILLIAMS, M., ARNERIC, S. P. AND HOLLADAY, M. W.: Structure-activity studies on 2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine (ABT-089): An orally bioavailable 3-pyridyl ether cholinergic channel modulator with cognition enhancing properties. J. Med. Chem. 40: 385-390, 1997.
35. MEYER, E. M., DE FIEBRE, C. M., HUNTER, B. E., SIMPKINS, C. E., FRAUWORTH, N. AND DE FIEBRE, N. E. C.: Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev. Res. 31: 127-134, 1994.
36. NEWHOUSE, P., POTTER, A. AND CORWIN, J.: Acute administration of the cholinergic channel activator ABT-418 improves learning in Alzheimer's disease. 2nd Annual Society for Research on Nicotine and Tobacco Conference, Washington, DC, 1996, Abstr. A39.
37. NEWHOUSE, P. A., POTTER, A., CORWIN, J. AND LENOX, R.: Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 108: 480-484, 1992.
38. NEWHOUSE, P. A., POTTER, A., CORWIN, J. AND LENOX, R.: Modeling the nicotinic receptor loss in dementia using the nicotinic antagonist mecamylamine: Effects on human cognitive functioning. Drug Dev. Res. 31: 71-79, 1994.
39. NEWHOUSE, P. A., SUNDERLAND, T., TARIOT, P. N., BLUMHARDT, C. L. WEINGARTNER, H. AND MELLOW, A.: Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95: 171-175, 1988.
40. PACKARD, M. G. AND MCGAUGH, J. L.: Double dissociation of fornix and caudate nucleus on acquisition of two water maze tasks: Further evidence for multiple memory systems. Behav. Neurosci. 106: 439-446, 1992
41. PRENDERGAST, M. A., TERRY, A. V., JR., JACKSON, W. J., MARSH, K.C., DECKER, M. W., ARNERIC, S. P. AND BUCCAFUSCO, J. J.: Improvement m accuracy of delayed recall in aged and nonaged monkeys intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology 130:276-284, 1997.
42. RIEKKINEN, P., JR., M. RIEKKINEN, SIRVIO, J. AND RIEKKINEN, P.; Effects of concurrent nicotinic antagonist and PCPA treatments on spatial and passive. avoidance learning. Brain Res. 575: 247-250, 1992.
43. RIEKKINEN, P., JR., RIEKKINEN, M. AND SIRVIÖ, J.: Cholinergic drugs regulate passive avoidance performance via the amygdala. J. Pharmacol Exp Ther. 267: 1484-1492, 1993.
44. RUSH, D. K.: Scopolamine amnesia of passive avoidance: a deficit of information acquisition. Behav. Neural Biol. 50: 255-274, 1988.
45. SAHAKIAN, B. J., OWEN, A. M., MORANT, N. J., EAGGER, S. A., BODDINGTON, S., CRAYTON, L., CROCKFORD, H. A., CROOKS, M., HILL, K. AND LEVY, R.; Futher analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 110: 395-401, 1993.
46. SOCCI, D. J., SANBERG, P. R. AND ARENDASH, G. W.: Nicotine enhances Morris water maze performance of young and aged rats. Neurobiol Agin 16: 857-860, 1995.
47. SULLIVAN, J. P., DONNELLY-ROBERTS, D., BRIGGS, C. A., ANDERSON, D. J., GOPALAKRISHNAN, M., XUE, I. C., PIATTONI-KAPLAN, M., MOLINARI, E., CAMPBELL, J. E., MCKENNA, D. G., GUNN, D. E., LIN, N. H., RYTHER, K. B., HE, Y., HOLLADAY, M. W., WONNACOTT, S., WILLIAMS, M. AND ARNERIC, S. P.: ABT-089[2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties, J.Pharmacol. Exp. Ther. 283: 235-246, 1997.
48. SWERDLOW, N. R. AND GEYER, M. A.: Prepulse inhibition of acoustic startle in rats after lesions of the pedunculopontine tegmental nucleus. Behav. Neurosci. 107: 104-117, 1993.
49. TERRY, A. V., JR., BUCCAFUSCO, J. J. AND JACKSON, W. J.: Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys Pharmacol. Biochem. Behav. 45: 925-929, 1993.
50. TILSON, H. A., MCLAMB, R. L., SHAW, S., RODGERS, B. C., PEDIADITAKIS, P. AND COOK, L.: Radial-arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents. Brain Res. 438: 83-94, 1988.
51. TURCHI, J., HOLLEY, L. AND SARTER, M.: Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. Psychopharmacology 118: 195-205, 1995.
52. WIDZOWSKI, D. V., CREGAN, E. AND BIALOBOK, P.: Effects of nicotinic agonists and antagonists on spatial working memory in normal adult and aged rats. Drug Dev. Res. 31: 24-31, 1994.
53. WILLNER, P., WISE, D. AND ELLIS, T.: Specific disruption of spatial behaviour in rats by central muscarinic receptor blockade. Psychopharmacology 90: 229-235, 1986.
54. WILSON, A. L., LANGLEY, L. K., MONLEY, J., BAUER, T., ROTTUNDA, S., MCFALLS, E., KOVERA, C. AND MCCARTEN, J. R.: Nicotine patches in Alzheimer's diseases Pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav 51: 509-14, 1995.
55. WOODRUFF-PAK, D. S., LI, Y.-T. AND KEM, W. R.: A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 645: 309-317, 1994.